Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : TGL WHAAAAAAAT! Alerts, thoughts, discussion. -- Ignore unavailable to you. Want to Upgrade?

To: Buckey who wrote (91247)	9/6/2001 9:47:55 AM
From: originunknown	Respond to of 150070

MONI has a very high debt LOAD! I am just flipping: buy under a dollar and sell at $1.18 eom

To: Buckey who wrote (91247)	9/6/2001 10:29:33 AM
From: Jim Bishop	Read Replies (2) \| Respond to of 150070

LOL here's your "dick creme" MacroChem: Topiglan Helps Erectile Function New York, Sep 06, 2001 (123Jump via COMTEX) -- Drug company MacroChem Corp. (MCHM) announced that Topiglan, a topical drug used to treat Erectile Dysfunction (ED), achieved statistically significant results in a recently completed, pivotal Phase 3 clinical trial. However, the drug failed to enable patients maintain erection until completion of intercourse. This ability is a benchmark required for approval of drugs used to treat ED. Topiglan contains 1% alprostadil, a synthetic hormone found in the male reproductive system, and 5% Soft Enhancer of Percutaneous Absorption (SEPA) - the company's drug-absorption excipient. Men apply Topiglan to the glans, or head, of the penis. According to MacroChem, Topiglan's alprostadil is safe for men with heart problems, unlike Pfixer Inc.'s (PFE) Viagra. Drugs taken orally may produce side effects affecting the central nervous and cardiovascular systems because the agent must be distributed by the circulatory system throughout the body to reach the intended site of action. Topligan achieved significant results on six questions related to erectile function, including, frequency of erections, confidence in ability to get and maintain an erection and ability to maintain an erection through ejaculation. Typically, when a drug is released from the site, it enters the bloodstream and passes through the lungs. With Topiglan, 90% of alprostadil is metabolized in the lungs, which accounts for the fact that side effects at the site of application were mild or moderate. The Lexington, Massachusetts company said that the early results are from a group of "protocol-conforming" patients who followed all instructions and conditions, rather than the full population of the study. Regulatory submissions normally include only results of the whole study. MacroChem announced that it will use a reformulated product and new dispensers to deliver "considerably more drug" in further studies. ED is characterized by the inability of a man to respond to sexual stimulation with a penile erection of sufficient firmness to penetrate his partner and to maintain that firmness through ejaculation. It is estimated that more than 30 million men in the United States suffer some degree of ED - be it mild, moderate or severe. Analysts expect that, by 2004, ED drug sales will total between $4 billion and $6 billion. MacroChem is engaged in the development of transdermal drug-delivery systems that allow drugs to be absorbed through the skin via creams, gels and patches. The company attracts business partners by applying its SEPA system to FDA-approved drugs. MacroChem has also developed a series of MacroDerm low molecular weight polymers for cosmetic use and the topical delivery of pharmaceuticals. Market capitalization is $173 million. The company competes against Cygnus Inc. (CYGN), Elan Corporation plc (ELN) and Novartis AG (NVS). Shares in MacroChem, which lost 7 cents, or 1.13%, to 6.15, in regular trading Wednesday, traded lower at 5.46 in the extended session after the announcement. CONTACT: For more information, contact 123Jump.com, Inc. Send email to: info@123jump.com Or, visit 123Jump at: 123jump.com All Rights Reserved. (c) Copyright: 2001 123jump.com, Inc. -0- * end of story *